Alterity Therapeutics to Present at MST Financial Webinar
Alterity Therapeutics Unveils Future in Investor Webinar
Alterity Therapeutics Seeks ASX Quotation
Alterity Therapeutics Plans New Share Issue
Alterity Shares Rise After Phase 2 Multiple System Atrophy Trial Interim Data
Trading Halt: Halt Status Updated at 9:05:00 AM ET: Quotation Resumption: News and Resumption Times
Alterity Therapeutics Announced Positive Interim Data From The ATH434-202 Open-label Phase 2 Clinical Trial In Patients With Multiple System Atrophy
Trading Halt: Halted at 3:58:05 A.m. ET - Trading Halt: Halt News Pending
Alterity Therapeutics Halts Trading for Clinical Update
Alterity Therapeutics Issues New Employee Options
Alterity Therapeutics to Present at the MST Access 'Hidden Gems in Life Sciences' Webinar
Alterity Therapeutics Unveils Critical Study Data
Alterity Therapeutics to Host Webcast Today on New Data From the BioMUSE Natural History Study
12 Health Care Stocks Moving In Monday's After-Market Session
Alterity Therapeutics Announces Option Cessation
12 Health Care Stocks Moving In Friday's After-Market Session
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As...
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November
JPMorgan Chase Ends Major Stake in Alterity Therapeutics
No Data